Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CD34+ and CD133+ Stem Cells for Chronic SCI
NCT02687672Phase 2Unknown
- Sponsor
- Stem Cells Arabia
- Start
- Jan 2016
- Primary completion
- Jun 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Autologous CD34+ and CD133+ Stem Cells in spinal cord injury (SCI), sponsored by Stem Cells Arabia. Status: unknown.
02
Drugs
Autologous CD34+ and CD133+ Stem Cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02687672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02687672.